Bruce A Malcolm
Overview
Explore the profile of Bruce A Malcolm including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
11
Citations
259
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Schneider E, Ashley G, Dillen L, Stoops B, Austin N, Malcolm B, et al.
Eur J Pharm Biopharm
. 2015 Apr;
93:254-9.
PMID: 25900863
We have previously developed a linker technology for half-life extension of peptides, proteins and small molecule drugs (1). The linkers undergo β-elimination reactions with predictable cleavage rates to release the...
2.
Benureau Y, Warter L, Malcolm B, Martin A
Virology
. 2010 Aug;
406(2):228-40.
PMID: 20701941
The hepatitis C virus (HCV) serine protease (NS3/4A) processes the NS3-NS5B segment of the viral polyprotein and also cleaves host proteins involved in interferon signaling, making it an important target...
3.
Tong X, Chase R, Skelton A, Chen T, Wright-Minogue J, Malcolm B
Antiviral Res
. 2006 Feb;
70(2):28-38.
PMID: 16448708
HCV NS3 protease variants resistant to the protease inhibitor SCH 503034 were selected. Three mutations, T54A, V170A and A156S mutations conferred low to moderate levels of resistance (<20-fold). Longer exposure...
4.
Tong X, Guo Z, Wright-Minogue J, Xia E, Prongay A, Madison V, et al.
Biochemistry
. 2006 Feb;
45(5):1353-61.
PMID: 16445277
HCV drug discovery efforts have largely focused on genotype 1 virus due to its prevalence and relatively poor response to current therapy. However, patients infected with genotype 2 and 3...
5.
Yi M, Tong X, Skelton A, Chase R, Chen T, Prongay A, et al.
J Biol Chem
. 2005 Dec;
281(12):8205-15.
PMID: 16352601
Drug resistance is a major issue in the development and use of specific antiviral therapies. Here we report the isolation and characterization of hepatitis C virus RNA replicons resistant to...
6.
Tong X, Malcolm B
Virus Res
. 2005 Sep;
115(2):122-30.
PMID: 16146661
Although establishment of the subgenomic replicon system has considerably facilitated genetic analysis of HCV replication, many details remain largely unknown. To initially test whether HCV replication could be affected in...
7.
Lahser F, Malcolm B
Anal Biochem
. 2004 Jan;
325(2):247-54.
PMID: 14751259
Current assays for the activity of viral RNA-dependent RNA polymerases (RdRps) are inherently end-point measurements, often requiring the use of radiolabeled or chemically modified nucleotides to detect reaction products. In...
8.
Wang W, Lahser F, Yi M, Wright-Minogue J, Xia E, Weber P, et al.
J Virol
. 2003 Dec;
78(2):700-9.
PMID: 14694101
Inspection of over 250 hepatitis C virus (HCV) genome sequences shows that a threonine is strictly conserved at the P1 position in the NS3-NS4A (NS3-4A) autoproteolysis junction, while a cysteine...
9.
Zhou S, Liu R, Baroudy B, Malcolm B, Reyes G
Virology
. 2003 Jun;
310(2):333-42.
PMID: 12781720
The recent development of in vitro hepatitis C virus (HCV) RNA replication systems has provided useful tools for studying the intracellular anti-HCV activity of ribavirin. Ribavirin has been shown to:...
10.
Lahser F, Wright-Minogue J, Skelton A, Malcolm B
Biotechniques
. 2003 Jan;
34(1):26-8.
PMID: 12545532
No abstract available.